![Mary Fenton](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mary Fenton
Finanzdirektor/CFO bei
CULLINAN THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 31.05.2026
Profil
Mary Kay Fenton is Director at Connecticut Business & Industry Association since 2018.
Ms. Fenton is Chief Financial Officer at Cullinan Therapeutics, Inc. starting in 2024.
Former roles include Independent Director at Oncorus, Inc. from 2019 to 2023, Vice President-Strategic Operations at Vertex Pharmaceuticals, Inc. from 2019 to 2021, Senior Manager-Technology Industry Group at PricewaterhouseCoopers LLP from 1991 to 2000, CFO, Principal Accounting Officer & Executive VP at Achillion Pharmaceuticals, Inc. from 2016 to 2018, President, Chief Executive & Financial Officer at Talaris Therapeutics, Inc. in 2023, and Chief Operating & Financial Officer at Semma Therapeutics, Inc. in 2019.
Education includes an MBA from the University of Connecticut School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.06.2026 | 127.921 ( 0,21 % ) | 2 Mio $ | 31.05.2026 |
Aktive Positionen von Mary Fenton
| Unternehmen | Position | Beginn |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Finanzdirektor/CFO | 29.04.2024 |
Connecticut Business & Industry Association
 Connecticut Business & Industry Association Miscellaneous Commercial ServicesCommercial Services Operates as a non profit organization that provides commercial support services | Direktor/Vorstandsmitglied | 06.12.2018 |
Ehemalige bekannte Positionen von Mary Fenton
| Unternehmen | Position | Ende |
|---|---|---|
| TOUE BIOPAR | Vorstandsvorsitzender | 01.10.2023 |
| ONCORUS, INC. | Direktor/Vorstandsmitglied | 27.07.2023 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01.02.2021 |
Semma Therapeutics, Inc.
 Semma Therapeutics, Inc. BiotechnologyHealth Technology Develops transformative therapies for patients who currently depend on insulin injections | Finanzdirektor/CFO | 01.10.2019 |
| ACHILLION PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 28.12.2018 |
Ausbildung von Mary Fenton
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
90
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Vertex Pharmaceuticals, Inc.
 Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, assurance, consulting and tax & business consulting services | Commercial Services |
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes treatments for infectious diseases | Health Technology |
College of the Holy Cross (Massachusetts)
 College of the Holy Cross (Massachusetts) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Connecticut Business & Industry Association
Connecticut Business & Industry Association Miscellaneous Commercial ServicesCommercial Services Operates as a non profit organization that provides commercial support services | Commercial Services |
University of Connecticut School of Business
 University of Connecticut School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Talaris Therapeutics, Inc.
 Talaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Develops transformative therapies for patients who currently depend on insulin injections | Health Technology |
Oncorus, Inc.
 Oncorus, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops next generation immunotherapy platform to treat cancer | Health Technology |
Cullinan Oncology, Inc.
 Cullinan Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Wählen Sie MarketScreener 
